scholarly journals Expression of CDK9 in endometrial cancer tissues and its effect on the proliferation of HEC-1B

2021 ◽  
Vol 16 (1) ◽  
pp. 1341-1346
Author(s):  
Wen Yang ◽  
Shaoyan Liu ◽  
Qiuping Luo ◽  
Xuexian Tan
Keyword(s):  
Endometrial Cancer ◽  
Malignant Tumors ◽  
Cyclin Dependent Kinase ◽  
Phosphatidylinositol 3 Kinase ◽  
Control Groups ◽  
Incidence And Mortality ◽  
Sirna Interference ◽  
Cancer Tissues ◽  
Si Rna ◽  
Proliferative Ability

Abstract Endometrial cancer (EC) is one of the most common malignant tumors in the female reproductive system, which has been threatening the life and health of many women. Its incidence and mortality rate remain high, resulting in a low survival rate. In this study, the expression of cyclin-dependent kinase 9 (CDK9) in EC tissues was investigated, and its effect on the proliferation of EC cell line HEC-1B was preliminarily analyzed. RT-qPCR and Western blotting showed that CDK9 mRNA and protein were significantly reduced in the small interfering (si)RNA interference group compared with the siRNA control and blank control groups. MTT assay showed that the EC cell proliferative ability was significantly decreased, and phosphorylated-phosphatidylinositol 3 kinase (p-PI3K)/PI3K and phosphorylated-protein kinase B (p-AKT)/AKT were significantly reduced in the siRNA interference group compared with the siRNA control and blank control groups. In conclusion, the high expression of CDK9 is a factor of poor prognosis in EC, and the reduction of CDK9 can inhibit HEC-1B cell proliferation, which may be related to the inhibition on the activation of the PI3K/AKT signaling pathway.

scholarly journals Correlation between Breast Ultrasound Microcalcification and the Prognosis of Breast Cancer

2021 ◽  
Vol 2021 ◽  
pp. 1-9
Author(s):  
Shanshan Xue ◽  
Qiaoling Zhao ◽  
Minghui Tai ◽  
Ning Li ◽  
Yun Liu
Keyword(s):  
Breast Cancer ◽  
Malignant Tumors ◽  
Survey Methods ◽  
Breast Ultrasound ◽  
Inflammatory Factors ◽  
Breast Cancer Patients ◽  
Incidence And Mortality ◽  
Ultrasound Technology ◽  
Breast Microcalcification ◽  
Cancer Tissues

Breast cancer is a common gynecological disease, and its incidence and mortality are higher than those of other common malignant tumors. Breast ultrasound technology is a new surgical method, which has the advantages of reducing postoperative complications, improving the quality of life of patients, and improving the prognosis of patients. Breast microcalcification is a new method for the treatment of tumors. Its mechanism is that the proliferation of breast cancer cell walls increases the inflammatory factors in the cancer tissues and enhances the formation of tumors and peripheral vascular thrombosis. Breast microcalcification in the treatment of breast cancer patients will have a more significant impact compared to ordinary antibiotics alone. For this reason, the microcalcification performance of breast ultrasound is worthy of study, and related research on prognosis is also indispensable. The purpose of this study is to improve the understanding of the ultrasound manifestations of breast cancer microcalcification and the prognosis of breast cancer. This article mainly applied statistical analysis as well as experimental and survey methods to conduct breast ultrasound examination on 100 patients and analyzed the ultrasound manifestations of breast cancer MCs from three aspects: location, shape, and distribution. The experimental results show that there is no correlation between the location and distribution of breast cancer MCs and the diameter of the cancer foci, but there is a certain correlation between the morphology (non-gravel-like calcification) and the diameter of the cancer foci (>5 cm). Among them, HER-2 overexpression accounted for 11.9% in the grit-like MCs group and 51% in the non-grit-like MCs group.

scholarly journals Identification of Hub Gene in Cervical Cancer by Weighted Gene Co-Expression Network Analysis

2021 ◽  
Author(s):  
huan Chen ◽  
huan Chen ◽  
Meiyuan Huang ◽  
Qunzhi Zhang ◽  
Qiong Xu ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Network Analysis ◽  
Molecular Mechanism ◽  
Malignant Tumors ◽  
Disease Free Survival ◽  
Interaction Network ◽  
The Cancer Genome Atlas ◽  
Node Degree ◽  
Incidence And Mortality ◽  
Cancer Tissues

Abstract Background:Cervical cancer(CC) is one of the most common malignant tumors in gynecology. Both its incidence and mortality are high. Despite advances in screening, diagnosis, prevention, and treatment, CC is still one of the leading causes of cancer-related death in women. However, in the pathogenesis of CC, the exact molecular mechanism is still unclear. It may be a multi-gene, multi-factor, multi-step, and multi-stage complex process. Hence, the pathogenesis and molecular mechanism of CC are the keys to effective treatment of it. In this study, we tried to identify candidate biomarkers for cervical cancer through weighted gene co-expression network analysis (WGCNA). Methods: The gene expression profile of CESC was downloaded from The Cancer Genome Atlas (TCGA) database. Differentially expressed genes (DEGs) were analyzed by the Limma package, and the gene co-expression module was constructed by WGCNA. Use the online website STRING to construct the protein interaction network of genes in significant modules, and then use Cytoscape analysis to find the 10 most important node degree genes. Results: Among these 10 genes, SOX9 expression was associated with the prognosis of cervical cancer patients. Immunohistochemical results from the online website human protein atlas showed that SOX9 protein expression was significantly higher in cervical cancer tissues than in normal cervical tissues. After collecting cancerous and paracancerous tissue specimens from 16 patients with cervical cancer, Q-PCR showed that the mRNA expression levels of SOX9 in cervical cancer tissues were significantly greater than those in normal adjacent tissues. Conclusions: The elevated expression of SOX9 is significantly related to the disease-free survival and overall survival of cervical cancer. Therefore, the SOX9 gene could be used as an indicator of cervical cancer diagnosis and prognosis.

scholarly journals Uterine serous carcinoma: key advances and novel treatment approaches

2021 ◽  
pp. ijgc-2021-002753
Author(s):  
J Stuart Ferriss ◽  
Britt K Erickson ◽  
Ie-Ming Shih ◽  
Amanda N Fader
Keyword(s):  
Endometrial Cancer ◽  
Black Women ◽  
Treatment Options ◽  
Molecular Genetic ◽  
Serous Carcinoma ◽  
Cancer Syndrome ◽  
Her2 Positive ◽  
Incidence And Mortality ◽  
History Of ◽  
Uterine Serous Carcinoma

The incidence and mortality rates from endometrial cancer continue to increase worldwide, while rates in most other cancers have either plateaued or declined considerably. Uterine serous carcinoma represents a fraction of all endometrial malignancies each year, yet this histology is responsible for nearly 40% of all endometrial cancer-related deaths. These deaths disproportionately affect black women, who have higher rates of advanced disease at diagnosis. Molecular genetic analyses reveal major alterations including TP53 mutation, PIK3CA mutation/amplification, ERBB2 amplification, CCNE1 amplification, FBXW7 mutation/deletion, PPP2R1A mutation, and somatic mutations involving homologous recombination genes. Clinical risk factors for uterine serous carcinoma include advancing age, a history of breast cancer, tamoxifen usage, and the hereditary breast–ovarian cancer syndrome. Surgery remains the cornerstone of treatment. Recent advances in our understanding of uterine serous carcinoma molecular drivers have led to development of targeted therapeutics that promise improved outcomes for patients. Overexpression or amplification of HER2 in uterine serous carcinoma carries a poor prognosis; yet this actionable target has led to the incorporation of several anti-HER2 therapies, including trastuzumab which, when added to conventional chemotherapy, is associated with improved survival for women with advanced and recurrent HER2-positive disease. The combination of pembrolizumab and lenvatinib is also a promising targeted treatment strategy for women with uterine serous carcinoma, with a recent phase II study suggesting a 50% response rate in women with recurrent disease. Several trials examining additional targeted agents are ongoing. Despite years of stalled progress, meaningful, tailored treatment options are emerging for patients with this uncommon and biologically aggressive endometrial cancer subtype.

Reduced Expression of Cyclin-Dependent Kinase Inhibitor p27Kip1 in Oral Malignant Tumors

Pathobiology ◽  
1999 ◽  
Vol 67 (4) ◽  
pp. 169-173 ◽  
Author(s):  
Reiko Ito ◽  
Wataru Yasui ◽  
Yuzo Ogawa ◽  
Satoru Toyosawa ◽  
Eiichi Tahara ◽  
...  
Keyword(s):  
Kinase Inhibitor ◽  
Malignant Tumors ◽  
Cyclin Dependent Kinase ◽  
Cyclin Dependent Kinase Inhibitor

scholarly journals Mortality from endometrial cancer in female population of Belgrade

2004 ◽  
Vol 61 (3) ◽  
pp. 267-272
Author(s):  
Vesna Pantovic ◽  
Mirjana Jarebinski ◽  
Tatjana Pekmezovic ◽  
Anita Knezevic ◽  
Darija Kisic
Keyword(s):  
Endometrial Cancer ◽  
Mortality Rate ◽  
Malignant Tumors ◽  
Age Groups ◽  
Mortality Rates ◽  
Mortality Decline ◽  
Female Population ◽  
Average Percentage ◽  
Standardized Mortality Rate

Data about mortality from malignant tumors of endometrium were analyzed in the Belgrade area during the period 1975-2000. The obtained results showed that the average percentage of endometrial cancer in mortality structure from all the cancers of female population was 2.65%. During the observed 26-years period, malignant tumors of endometrium constituted 17.38% of all the tumors of gynecological localization. The standardized mortality rate in 1975 (population worldwide used as a standard) 7.06/100 000 population while in 2000 it was 1.78/100 000 population, respectively, which showed almost fourfold mortality decline during the observed period (y=4.72-0.16x). A trend of declining risk of dying from endometrial cancer was present in all the age groups. The obtained results indicated that in the observed period the average mortality rates ranged from 0.14/100 000 population in females aged up to 34 years (y=0.30-0.01x), and reached the highest value in females aged 65-74 years (14.57/100 000; y=23.43-0.66x), and 75 years of age and over (19.62/100 000; y=31.17-0.85x).

scholarly journals Role of Precision Oncology in Type II Endometrial and Prostate Cancers in the African Population: Global Cancer Genomics Disparities

2022 ◽  
Vol 23 (2) ◽  
pp. 628
Author(s):  
Rahaba Marima ◽  
Rodney Hull ◽  
Mandisa Mbeje ◽  
Thulo Molefi ◽  
Kgomotso Mathabe ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Endometrial Cancer ◽  
African Ancestry ◽  
African Population ◽  
Precision Oncology ◽  
Type Ii ◽  
Incidence And Mortality ◽  
Prostate Cancers ◽  
The Relationship

Precision oncology can be defined as molecular profiling of tumors to identify targetable alterations. Emerging research reports the high mortality rates associated with type II endometrial cancer in black women and with prostate cancer in men of African ancestry. The lack of adequate genetic reference information from the African genome is one of the major obstacles in exploring the benefits of precision oncology in the African context. Whilst external factors such as the geography, environment, health-care access and socio-economic status may contribute greatly towards the disparities observed in type II endometrial and prostate cancers in black populations compared to Caucasians, the contribution of African ancestry to the contribution of genetics to the etiology of these cancers cannot be ignored. Non-coding RNAs (ncRNAs) continue to emerge as important regulators of gene expression and the key molecular pathways involved in tumorigenesis. Particular attention is focused on activated/repressed genes and associated pathways, while the redundant pathways (pathways that have the same outcome or activate the same downstream effectors) are often ignored. However, comprehensive evidence to understand the relationship between type II endometrial cancer, prostate cancer and African ancestry remains poorly understood. The sub-Saharan African (SSA) region has both the highest incidence and mortality of both type II endometrial and prostate cancers. Understanding how the entire transcriptomic landscape of these two reproductive cancers is regulated by ncRNAs in an African cohort may help elucidate the relationship between race and pathological disparities of these two diseases. This review focuses on global disparities in medicine, PCa and ECa. The role of precision oncology in PCa and ECa in the African population will also be discussed.

scholarly journals Multi-Omics Analysis Identifying Key Biomarkers in Ovarian Cancer

2020 ◽  
Vol 27 (1) ◽  
pp. 107327482097667
Author(s):  
Ju-Yueh Li ◽  
Chia-Jung Li ◽  
Li-Te Lin ◽  
Kuan-Hao Tsui
Keyword(s):  
Ovarian Cancer ◽  
Protein Interactions ◽  
Malignant Tumors ◽  
Single Gene ◽  
Protein Protein Interactions ◽  
Normal Tissues ◽  
Human Protein Atlas ◽  
Copy Number Changes ◽  
And Function ◽  
Cancer Tissues

Ovarian cancer is one of the most common malignant tumors. Here, we aimed to study the expression and function of the CREB1 gene in ovarian cancer via the bioinformatic analyses of multiple databases. Previously, the prognosis of ovarian cancer was based on single-factor or single-gene studies. In this study, different bioinformatics tools (such as TCGA, GEPIA, UALCAN, MEXPRESS, and Metascape) have been used to assess the expression and prognostic value of the CREB1 gene. We used the Reactome and cBioPortal databases to identify and analyze CREB1 mutations, copy number changes, expression changes, and protein–protein interactions. By analyzing data on the CREB1 differential expression in ovarian cancer tissues and normal tissues from 12 studies collected from the “Human Protein Atlas” database, we found a significantly higher expression of CREB1 in normal ovarian tissues. Using this database, we collected information on the expression of 25 different CREB-related proteins, including TP53, AKT1, and AKT3. The enrichment of these factors depended on tumor metabolism, invasion, proliferation, and survival. Individualized tumors based on gene therapy related to prognosis have become a new possibility. In summary, we established a new type of prognostic gene profile for ovarian cancer using the tools of bioinformatics.

scholarly journals The Association and Significance of p53 in Gynecologic Cancers: The Potential of Targeted Therapy

2019 ◽  
Vol 20 (21) ◽  
pp. 5482 ◽  
Author(s):  
Mitsuhiro Nakamura ◽  
Takeshi Obata ◽  
Takiko Daikoku ◽  
Hiroshi Fujiwara
Keyword(s):  
Cervical Cancer ◽  
Endometrial Cancer ◽  
Malignant Tumors ◽  
P53 Protein ◽  
P53 Gene ◽  
Phase Iii ◽  
Significant Prognostic Factor ◽  
Double Positive ◽  
P53 Overexpression ◽  
Tp53 Mutations

Dysfunction of p53 is observed in the many malignant tumors. In cervical cancer, p53 is inactivated by degradation through the complex with human papilloma virus (HPV) oncoprotein E6 and E6-associated protein (E6AP), an E3 ubiquitin protein ligase. In endometrial cancer, overexpression of p53 in immunohistochemistry is a significant prognostic factor. A discrepancy between p53 overexpression and TP53 mutations is observed in endometrioid endometrial cancer, indicating that the accumulation of p53 protein can be explained by not only gene mutations but also dysregulation of the factors such as ERβ and MDM2. Furthermore, the double-positive expression of immunoreactive estrogen receptor (ER) β and p53 proteins is closely associated with the incidence of metastasis and/or recurrence. High-grade serous ovarian carcinoma (HGSC) arises from secretary cells in the fallopian tube. The secretary cell outgrowth (SCOUT) with TP53 mutations progresses to HGSC via the p53 signature, serous intraepithelial lesion (STIL), and serous intraepithelial carcinoma (STIC), indicating that TP53 mutation is associated with carcinogenesis of HGSC. Clinical application targeting p53 has been approved for some malignant tumors. Gene therapy by the adenovirus-mediated p53 gene transfer system is performed for head and neck cancer. A clinical phase III trial using MDM2/X inhibitors, idasanutlin (RG7388) combined with cytarabine, is being performed involving relapse/refractory acute myeloid leukemia patients. The use of adenoviruses as live vectors which encode wild-type p53 has given promising results in cervical cancer patients.

Sign in / Sign up

Export Citation Format

Share Document